Sign In
Buy DRMA
$1.27
-0.0900 (-6.62%)
At Close: Jun 03, 2026
Dermata Therapeutics Announces Presentation of Abstract at the European Academy of Dermatology and Venereology Congress 2025
01:00am, Wednesday, 17'th Sep 2025
- Abstract highlights additional primary and secondary data from Phase 3 STAR-1 clinical study of XYNGARI™ for the treatment of moderate-to-severe acne - SAN DIEGO, CA / ACCESS Newswire / September
Dermata Therapeutics to Present at the Life Sciences Virtual Investor Forum September 18th
08:35am, Tuesday, 16'th Sep 2025
SAN DIEGO, Sept. 16, 2025 (GLOBE NEWSWIRE) -- Dermata Therapeutics to Present at the Life Sciences Virtual Investor Forum September 18 th Dermata invites individual and institutional investors, as wel
Dermata Therapeutics Announces Strategic Pivot to Over-the-Counter Skin Care Treatments
08:00am, Wednesday, 10'th Sep 2025
SAN DIEGO, CA / ACCESS Newswire / September 10, 2025 / Dermata Therapeutics, Inc. (Nasdaq:DRMA)(Nasdaq:DRMAW) ("Dermata" or the "Company"), a science-driven leader in dermatologic solutions, today ann
Dermata Therapeutics Provides Corporate Update and Reports Second Quarter 2025 Financial Results
05:00pm, Wednesday, 13'th Aug 2025
- Dermata announced additional positive data from its XYNGARI™ Phase 3 Spongilla Treatment of Acne Research (STAR-1) clinical trial- - Raised $8.8 million in gross proceeds from a private placement
Dermata Receives Notice of Grant of Australian Patent for Topical Botulinum Toxin Treatment for Hyperhidrosis
08:00am, Tuesday, 08'th Jul 2025
- This is the Company's second granted patent for DMT410, using its Spongilla technology to topically deliver botulinum toxin for hyperhidrosis - - The Company recently entered into a Clinical Trial C
Dermata's XYNGARI(TM) Phase 3 Trial Hits Statistically Significant Difference at 4 Weeks
08:30am, Tuesday, 15'th Apr 2025
- Dermata previously announced XYNGARI(TM) produced highly statistically significant topline data for all primary endpoints at week 12 in Phase 3 trial - - Additional data analysis revealed that XYNGA
Dermata Therapeutics Announces Exercise of Warrants for $6.2 Million in Gross Proceeds Priced At-the-Market Under Nasdaq Rules
08:15pm, Thursday, 27'th Mar 2025
SAN DIEGO, CA / ACCESS Newswire / March 27, 2025 / Dermata Therapeutics, Inc. (NASDAQ:DRMA)(NASDAQ:DRMAW) ("Dermata," or the "Company"), a late-stage biotechnology company focused on the treatment of
Nano-Cap Dermata Therapeutics Unveils Positive Data From Once Weekly Drug Study For Acne
10:21am, Thursday, 27'th Mar 2025
Dermata Therapeutics, Inc. DRMA stock is trading higher on Thursday.
BREAKING: Dermata's XYNGARI™ Phase 3 Trial Topline Data Meets All Primary Endpoints
08:00am, Thursday, 27'th Mar 2025
- XYNGARI™ achieved its primary endpoints, demonstrating highly statistically significant and clinically meaningful improvement in acne - - XYNGARI™ is the first once-weekly topical product cand
Dermata Therapeutics Provides Corporate Update and Reports Year End 2024 Financial Results
04:16pm, Monday, 17'th Mar 2025
- Dermata expects to announce topline results from its XYNGARI™ Phase 3 Spongilla Treatment of Acne Research (STAR-1) clinical trial by end of March 2025 - - The Company recently entered into a Clin
Dermata Announces that Last Patient Completes Last Visit in Pivotal XYNGARI™ Phase 3 STAR-1 Clinical Trial for Acne
08:03am, Tuesday, 04'th Mar 2025
- STAR-1 topline results expected by the end of March 2025 - - Over 30 million acne patients seek treatment in the U.S. each year - - XYNGARI™ Phase 3 STAR-1 trial enrolled 520 patients with moderat
Dermata Receives Notice of Acceptance of Australian Patent Application for Topical Botulinum Toxin Treatment for Hyperhidrosis
07:58am, Tuesday, 25'th Feb 2025
- This would be Dermata's second patent for DMT410, if issued, using its Spongilla technology to topically deliver botulinum toxin for hyperhidrosis - - The Company recently entered into a Clinical Tr
Dermata to Present on BioPub on January 31, 2025
04:05pm, Wednesday, 29'th Jan 2025
- Dermata's Chief Executive Officer and Chief Development Officer will provide a corporate update and answer live questions from the biotech investment community - SAN DIEGO, CA / ACCESS Newswire / Ja
Dermata Expands Patent Portfolio with Issuance of New U.S. Patent for Next-Generation Acne Treatment
04:05pm, Tuesday, 28'th Jan 2025
- This is Dermata's first issued U.S. patent for XYNGARI™, which uses its Spongilla technology to topically treat acne - - Dermata expects to announce topline results from its STAR-1 Phase 3 XYNGARI
Dermata Therapeutics Announces Closing of $2.55 Million Private Placement Priced At-The-Market Under Nasdaq Rules
04:15pm, Thursday, 23'rd Jan 2025
SAN DIEGO, CA / ACCESS Newswire / January 23, 2025 / Dermata Therapeutics, Inc. (NASDAQ:DRMA)(NASDAQ:DRMAW) ("Dermata," or the "Company"), a late-stage biotechnology company focused on the treatment o
